AbbVie, Genmab's Epkinly shows promise in follicular lymphoma. Will FDA get on board?
Fierce Pharma
JUNE 28, 2023
Merely a month into an FDA approval, AbbVie and Genmab’s bispecific drug Epkinly has chalked up a positive readout that might enable an expansion in blood cancer, although the exact regulatory path | Merely a month into an FDA approval, AbbVie and Genmab’s bispecific drug Epkinly has chalked up a positive readout that might enable an expansion in blood (..)
207 
Let's personalize your content